EMA Panel Finalises Safety Probe Into Richter’s Fibroid Drug Esmya
Executive Summary
Gedeon Richter’s uterine fibroid drug, Esmya (ulipristal acetate), is expected to be the subject of a safety recommendation by the EMA’s pharmacovigilance committee this week.
You may also be interested in...
14 Approvals To Look Out For In Q3
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
The latest drug development news and highlights from our US FDA Performance Tracker.
Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns
Restrictions placed on the use of Gedeon Richter’s uterine fibroid drug Esmya by the European Medicines Agency could significantly dent the product’s sales in the EU, and could also have a knock-on effect in the US, where the FDA accepted an NDA filing for the drug in October 2017.